600587.SH
新华医疗
SSE · Healthcare · Medical - Devices · CN
CNY 12.23
−1.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.7B | 9.7B | 10.0B | 10.0B | 9.3B |
| Cost of Revenue | 7.2B | 7.3B | 7.4B | 7.4B | 6.8B |
| Gross Profit | 2.5B | 2.4B | 2.6B | 2.7B | 2.5B |
| Operating Expenses | |||||
| R&D Expense | 423.1M | 442.0M | 436.1M | 443.4M | 401.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 410.9M | 406.5M | 422.1M | 520.2M | 461.3M |
| Selling & Marketing Expense | 904.0M | 894.0M | 868.6M | 823.5M | 887.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.8B | 1.8B | 1.8B | 1.9B | 1.9B |
| Cost and Expenses | 9.1B | 9.1B | 9.2B | 9.2B | 8.7B |
| Operating Income (EBIT) | 547.9M | 590.9M | 798.5M | 757.0M | 585.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 550.3M | 591.1M | 795.7M | 738.6M | 576.1M |
| Income Tax Expense | 58.7M | 63.0M | 103.8M | 62.1M | 49.2M |
| Bottom Line | |||||
| Net Income | 489.9M | 526.3M | 691.6M | 654.0M | 500.1M |
| Earnings from Cont. Ops | 491.6M | 528.1M | 691.9M | 676.5M | 526.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 489.9M | 526.3M | 691.6M | 654.0M | 500.1M |
| Per Share | |||||
| Basic EPS | CN¥0.81 | CN¥0.87 | CN¥1.14 | CN¥1.10 | CN¥1.23 |
| Diluted EPS | CN¥0.81 | CN¥0.87 | CN¥1.14 | CN¥1.09 | CN¥1.23 |
| Revenue Per Share | CN¥15.61 | CN¥16.09 | CN¥16.52 | CN¥16.84 | CN¥22.83 |
| Shares | |||||
| Basic Shares Outstanding | 620.3M | 605.0M | 606.7M | 594.5M | 406.6M |
| Diluted Shares Outstanding | 620.3M | 605.0M | 606.7M | 594.5M | 406.6M |
| Profitability Metrics | |||||
| EBITDA | — | 845.1M | 1.0B | 989.1M | 818.8M |
| D&A | — | 254.3M | 235.5M | 232.1M | 233.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026